The HOST-BR trial found that a 3-month dual antiplatelet therapy regimen after percutaneous coronary intervention balances ischemic and bleeding risks.
The post HOST-BR: Searching for the Optimal Duration of DAPT After PCI first appeared on Physician’s Weekly.
